Evidence-based management of statin myopathy

Current Atherosclerosis Reports

Volumn 12, Issue 5, 2010, Pages 322-330

  Harper, Charles R ^a   Jacobson, Terry A ^b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

Author keywords

Algorithm; Cholesterol; Coenzyme Q 10; Colesevelam; Creatine kinase; Cytochrome metabolism; Drug interactions; Drug safety; Ezetimibe; Fibrates; Lipids; Management; Muscle symptoms; Myalgia; Myopathy; Myositis; Red yeast rice; Rhabdomyolysis; Statin; Vitamin D

Indexed keywords

ATORVASTATIN; CALCIUM; COLESEVELAM; CYTOCHROME; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOPRENOID; MEVINOLIN; ORGANIC ANION TRANSPORTER 2; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; UBIDECARENONE; VITAMIN D; XUEZHIKANG;

CALCIUM SIGNALING; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EXCRETION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; EVIDENCE BASED MEDICINE; FATIGUE; HEART INFARCTION; HEREDITY; HUMAN; HYPERLIPIDEMIA; INCIDENCE; ISCHEMIC HEART DISEASE; LOW BACK PAIN; LOW DRUG DOSE; METABOLIC SYNDROME X; MUSCLE INJURY; MYALGIA; MYOPATHY; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PATIENT MONITORING; PHARMACODYNAMICS; REVIEW; RHABDOMYOLYSIS; RISK FACTOR; SCREENING; SINGLE NUCLEOTIDE POLYMORPHISM; STATIN MYOPATHY; WEAKNESS;

ALGORITHMS; CARDIOVASCULAR DISEASES; CHOLESTEROL; EVIDENCE-BASED MEDICINE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MUSCULAR DISEASES; PROGNOSIS; RISK FACTORS; UBIQUINONE; VITAMIN D; VITAMINS;

EID: 77956262854     PISSN: 15233804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11883-010-0120-9     Document Type: Review

References (45)

1. M Law AR Rudnicka 2006 Statin safety: a systematic review Am J Cardiol 97 52C 60C 10.1016/j.amjcard.2005.12.010 1:CAS:528:DC%2BD28XkvF2gsr4%3D 16581329
2. M Mitka 2003 Expanding statin use to help more at-risk patients is causing financial heartburn JAMA 290 2243 2245 10.1001/jama.290.17.2243 1:CAS:528:DC%2BD3sXovVeqtbk%3D 14600168
3. RC Pasternak SC Smith Jr CN Bairey-Merz, et al. 2002 ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins Circulation 106 1024 1028 10.1161/01.CIR.0000032466.44170.44 12186811
4. JM McKenney MH Davidson TA Jacobson JR Guyton 2006 National Lipid Association Statin Safety Assessment Task Force: Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force Am J Cardiol 97 89C 94C 10.1016/j.amjcard.2006.02.030 1:CAS:528: DC%2BD28XkvF2gs78%3D 16581336
5. CR Harper TA Jacobson 2007 The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis Curr Opin Lipidol 18 401 408 10.1097/MOL. 0b013e32825a6773 1:CAS:528:DC%2BD2sXnsVCkuro%3D 17620856
6. D Gaist LA Rodriguez C Huerta, et al. 2001 Lipid-lowering drugs and risk of myopathy: a population-based follow-up study Epidemiology 12 565 569 10.1097/00001648-200109000-00017 1:STN:280:DC%2BD3MvlvVyrtA%3D%3D 11505177
7. RL Shanahan JA Kerzee BG Sandhoff, et al. 2005 Low myopathy rates associated with statins as monotherapy or combination therapy with interacting drugs in a group model health maintenance organization Pharmacotherapy 25 345 351 10.1592/phco.25.3.345.61606 1:CAS:528:DC%2BD2MXisFSjtbk%3D 15843281
8. E Bruckert G Hayem S Dejager, et al. 2005 Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients-the PRIMO study [see comment] Cardiovasc Drugs Ther 19 403 414 10.1007/s10557-005-5686-z 1:CAS:528:DC%2BD28XhtlGku7w%3D 16453090
9. MG Mohaupt RH Karas EB Babiychuk, et al. 2009 Association between statin-associated myopathy and skeletal muscle damage CMAJ Can Med Assoc J 181 E11 E18 10.1503/cmaj.081785
10. C Hodel 2002 Myopathy and rhabdomyolysis with lipid-lowering drugs Toxicol Lett 128 159 168 10.1016/S0378-4274(02)00010-3 1:CAS:528: DC%2BD38XhsFCktbw%3D 11869826
11. OP Flint BA Masters RE Gregg SK Durham 1997 Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro Toxicol Appl Pharmacol 145 91 98 10.1006/taap.1997.8131 1:CAS:528: DyaK2sXktl2hurw%3D 9221828
12. SK Baker 2005 Molecular clues into the pathogenesis of statin-mediated muscle toxicity Muscle Nerve 31 572 580 10.1002/mus.20291 1:CAS:528: DC%2BD2MXksVylsbw%3D 15712281
13. L Marcoff PD Thompson 2007 The role of coenzyme Q10 in statin-associated myopathy: a systematic review [see comment] J Am Coll Cardiol 49 2231 2237 10.1016/j.jacc.2007.02.049 1:CAS:528:DC%2BD2sXmtlWisrg%3D 17560286
14. AN Baer RL Wortmann 2007 Myotoxicity associated with lipid-lowering drugs Curr Opin Rheumatol 19 67 73 1:CAS:528:DC%2BD28Xht1OhtrrM 17143099
15. H Päivä KM Thelen R Van Coster, et al. 2005 High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial Clin Pharmacol Ther 78 60 68 10.1016/j.clpt.2005.03.006 16003294
16. R Laaksonen K Jokelainen T Sahi, et al. 1995 Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short-term simvastatin treatment in humans Clin Pharmacol Ther 57 62 66 10.1016/0009-9236(95)90266-X 1:STN:280:DyaK2M7ivFejtA%3D%3D 7828383
17. WH Schaefer JW Lawrence AF Loughlin, et al. 2004 Evaluation of ubiquinone concentration and mitochondrial function relative to cerivastatin-induced skeletal myopathy in rats Toxicol Appl Pharmacol 194 10 23 10.1016/j.taap.2003. 08.013 1:CAS:528:DC%2BD2cXjtFagsw%3D%3D 14728975
18. AJ Dirks KM Jones 2006 Statin-induced apoptosis and skeletal myopathy Am J Physiol Cell Physiol 291 C1208 1212 10.1152/ajpcell.00226.2006 1:CAS:528:DC%2BD2sXjvVKq 16885396
19. C Guijarro LM Blanco-Colio M Ortego, et al. 1998 3-Hydroxy-3- methylglutaryl coenzyme a reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture Circ Res 83 490 500 1:CAS:528:DyaK1cXlvFCgu7o%3D 9734471
20. P Sirvent J Mercier G Vassort A Lacampagne 2005 Simvastatin triggers mitochondria-induced Ca2+ signaling alteration in skeletal muscle Biochem Biophys Res Commun 329 1067 1075 10.1016/j.bbrc.2005.02.070 1:CAS:528: DC%2BD2MXitVChtbY%3D 15752763
21. PP Toth CR Harper TA Jacobson 2008 Clinical characterization and molecular mechanisms of statin myopathy Expert Rev Cardiovasc Ther 6 955 969 10.1586/14779072.6.7.955 1:CAS:528:DC%2BD1cXpt1eku7k%3D 18666846
22. HB Brewer Jr 2003 Benefit-risk assessment of rosuvastatin 10 to 40 milligrams Am J Cardiol 92 23K 29K 10.1016/S0002-9149(03)00779-3 1:CAS:528:DC%2BD3sXnvVSht7o%3D 12948873
23. •• Jacobson TA: Toward "pain-free" statin prescribing: clinical algorithm for diagnosis and management of myalgia [see comment]. Mayo Clin Proc 2008, 83:687-700. This is an excellent overview of statin-induced myalgia with one of the first published algorithms on myalgia management strategies.
24. CV Venero PD Thompson 2009 Managing statin myopathy Endocrinol Metab Clin North Am 38 121 136 10.1016/j.ecl.2008.11.002 1:CAS:528:DC%2BD1MXkt1eks7w%3D 19217515
25. GD Vladutiu Z Simmons PJ Isackson, et al. 2006 Genetic risk factors associated with lipid-lowering drug-induced myopathies Muscle Nerve 34 153 162 10.1002/mus.20567 1:CAS:528:DC%2BD28Xosl2jtbs%3D 16671104
26. •• Group SC, Link E, Parish S, et al.: SLCO1B1 variants and statin-induced myopathy - a genomewide study [see comment]. N Engl J Med 2008, 359:789-799. This was one of the first studies to identify genetic predictors of myopathy, such as specific defects in the statin organic anion transporting polypeptide system responsible for hepatic uptake of statins.
27. CR Harper TA Jacobson 2008 Managing dyslipidemia in chronic kidney disease J Am Coll Cardiol 51 2375 2384 10.1016/j.jacc.2008.03.025 1:CAS:528:DC%2BD1cXnsFChurc%3D 18565393
28. DJ Graham JA Staffa D Shatin, et al. 2004 Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs JAMA 292 2585 2590 10.1001/jama.292.21.2585 1:CAS:528:DC%2BD2cXhtVegurzM 15572716
29. PH Jones MH Davidson 2005 Reporting rate of rhabdomyolysis with fenofibrate∈+∈statin versus gemfibrozil∈+∈any statin Am J Cardiol 95 120 122 10.1016/j.amjcard.2004.08.076 1:CAS:528:DC%2BD2cXhtFahs7jE 15619408
30. T Prueksaritanont JJ Zhao B Ma, et al. 2002 Mechanistic studies on metabolic interactions between gemfibrozil and statins J Pharmacol Exp Ther 301 1042 1051 10.1124/jpet.301.3.1042 1:CAS:528:DC%2BD38XktlGjsbw%3D 12023536
31. G Caso P Kelly MA McNurlan WE Lawson 2007 Effect of coenzyme q10 on myopathic symptoms in patients treated with statins Am J Cardiol 99 1409 1412 10.1016/j.amjcard.2006.12.063 1:CAS:528:DC%2BD2sXlt1equr4%3D 17493470
32. JM Young CM Florkowski SL Molyneux, et al. 2007 Effect of coenzyme Q(10) supplementation on simvastatin-induced myalgia Am J Cardiol 100 1400 1403 10.1016/j.amjcard.2007.06.030 1:CAS:528:DC%2BD2sXhtF2itLbF 17950797
33. P Lips 2006 Vitamin D physiology Prog Biophys Mol Biol 92 4 8 10.1016/j.pbiomolbio.2006.02.016 1:CAS:528:DC%2BD28XlsFKrsbo%3D 16563471
34. HA Bischoff-Ferrari T Dietrich EJ Orav, et al. 2004 Higher 25-hydroxyvitamin D concentrations are associated with better lower-extremity function in both active and inactive persons aged∈>∈or =60 y Am J Clin Nutr 80 752 758 1:CAS:528:DC%2BD2cXnsVWhsrg%3D 15321818
35. MZ Erkal J Wilde Y Bilgin, et al. 2006 High prevalence of vitamin D deficiency, secondary hyperparathyroidism and generalized bone pain in Turkish immigrants in Germany: identification of risk factors Osteoporos Int 17 1133 1140 10.1007/s00198-006-0069-2 1:CAS:528:DC%2BD28XmsFOmt70%3D 16718398
36. W Ahmed N Khan CJ Glueck, et al. 2009 Low serum 25 (OH) vitamin D levels (<32 ng/mL) are associated with reversible myositis-myalgia in statin-treated patients Transl Res 153 11 16 10.1016/j.trsl.2008.11.002 1:CAS:528: DC%2BD1cXhsFagsLvE 19100953
37. IF Gazi SS Daskalopoulou DR Nair DP Mikhailidis 2007 Effect of ezetimibe in patients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin Curr Med Res Opin 23 2183 2192 10.1185/030079907X226267 1:CAS:528:DC%2BD2sXht12rtL%2FF 17692154
38. EA Stein CM Ballantyne E Windler, et al. 2008 Efficacy and tolerability of fluvastatin XL 80 mg alone, ezetimibe alone, and the combination of fluvastatin XL 80 mg with ezetimibe in patients with a history of muscle-related side effects with other statins Am J Cardiol 101 490 496 10.1016/j.amjcard. 2007.09.099 1:CAS:528:DC%2BD1cXhslektL8%3D 18312764
39. JM Backes CV Venero CA Gibson, et al. 2008 Effectiveness and tolerability of every-other-day rosuvastatin dosing in patients with prior statin intolerance Ann Pharmacother 42 34 346
40. VG Athyros K Tziomalos AI Kakafika, et al. 2008 Effectiveness of ezetimibe alone or in combination with twice a week Atorvastatin (10 mg) for statin intolerant high-risk patients Am J Cardiol 101 483 485 10.1016/j.amjcard.2007.09.096 1:CAS:528:DC%2BD1cXhslekt7c%3D 18312762
41. SM Rivers MP Kane RS Busch, et al. 2007 Colesevelam hydrochloride- ezetimibe combination lipid-lowering therapy in patients with diabetes or metabolic syndrome and a history of statin intolerance Endocr Pract 13 11 16 17360295
42. Z Lu W Kou B Du, et al. 2008 Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction Am J Cardiol 101 1689 1693 10.1016/j.amjcard.2008.02.056 18549841
43. Becker DJ, Gordon RY, Halbert SC, et al.: Red yeast rice for dyslipidemia in statin-intolerant patients: a randomized trial [see comment]. [summary for patients in Ann Intern Med. 2009 Jun 16;150(12):I28; PMID: 19528545]. Ann Intern Med 2009, 150:830-839.
44. JR Guyton 2006 Benefit versus risk in statin treatment Am J Cardiol 97 95C 97C 10.1016/j.amjcard.2005.12.016 16581337
45. TJ Wilt HE Bloomfield R MacDonald, et al. 2004 Effectiveness of statin therapy in adults with coronary heart disease Arch Intern Med 164 1427 1436 10.1001/archinte.164.13.1427 1:CAS:528:DC%2BD2cXmsVKqsb0%3D 15249352